Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Centessa Pharmaceuticals + Eli Lilly

pending

$CNTA acquired by Eli Lilly for $7.8B

Deal Summary

Deal Value
$7.8B
Price/Share
$38
Announced
Mar 31, 2026
Expected Close
TBD

Fund Positioning

10 of 20 tracked specialist biotech funds held $CNTA — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Avoro Capital Advisors14.6M$364.0MMar 2025Yes
EcoR1 Capital3.1M$77.9MSep 2025Yes
Perceptive Advisors2.9M$73.0MMar 2025Yes
Deep Track Capital2.0M$50.0MDec 2025Yes
RTW Investments1.8M$44.8MMar 2025Yes
Cormorant Asset Management1.3M$33.1MDec 2025Yes
Commodore Capital1.0M$25.0MMar 2025Yes
Baker Bros. Advisors671K$16.8MMar 2025Yes
Driehaus Capital516K$12.5MMar 2025Yes
Rock Springs Capital324K$8.1MSep 2025Yes
← All biotech acquisitions